This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

In The News

/In The News

ArmaGen Update on Hurler Syndrome Development Program

AGT-181: Investigational Therapy for the Treatment of Patients with Hurler Syndrome AGT-181 is an investigational enzyme replacement therapy designed to treat both the body-related and central nervous system-related symptoms and complications of MPS I. Currently approved treatments for MPS I are unable to penetrate the blood-brain barrier (BBB), a filter that protects the brain from harmful substances like toxins and bacteria but allows [...]

Pivotal phase gene transfer clinical trial for Mucopolysaccharidosis Type IIIA delivering LYS-SAF302

Pivotal phase gene transfer clinical trial for Mucopolysaccharidosis Type IIIA delivering LYS-SAF302 What is the purpose of this study? Lysogene is preparing a pivotal phase 2-3 clinical trial to assess the efficacy of direct to CNS delivery of LYS-SAF302 in improving or stabilizing the neurodevelopmental status of MPS IIIA patients. The trial will start in the [...]

BioMarin Presents Interim Data Treatment of MPS IIIB

News Release Issued: Sep 6, 2017 (8:00am PDT) To view this release online and get more information about BioMarin : IR Room visit: http://investors.biomarin.com/2017-09-06-BioMarin-Presents-Interim-Data-of-Phase-1-2-Study-of-BMN-250-for-Treatment-of-Sanfilippo-B-Syndrome-MPS-IIIB-at-13th-International-Congress-of-Inborn-Errors-of-Metabolism-ICIEM-2017 BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017 Preliminary biomarker [...]

Donate Today!

Donate Today! Helping us fulfill our mission of supporting families affected by MPS & related diseases and funding research for a cure is the greatest gift anyone can give. Interested in organizing a fundraising event for the Canadian MPS Society, please contact our head office, so we can assist you and help make your event [...]

New Brunswick Announces Rare Disease Plan!

Rare diseases drug plan established 28 July 2014 FREDERICTON (GNB) – The provincial government has established the New Brunswick Drugs for Rare Diseases Plan which will provide assistance to those with certain rare diseases who face high drug costs. “The cost of drugs to treat rare diseases can sometimes reach a million dollars per year per [...]

MPS IV A Families in the News!

MPS IV A Families in the News! Calgary’s Barb Larson appeared on AM630 CHED’s “Tencer and Grose” show in Edmonton, Alberta on July 9 to talk about her daughter Savannah’s journey with MPS IVA, Health Canada approval of VIMIZIM and the need for publicly funded access to treatment. Listen to the interview here: https://soundcloud.com/#630ched/tg-july-9-hr2  (beginning at [...]

Cornwall family’s spirit gets a lift

Cornwall family's spirit gets a lift By Adam Brazeau CORNWALL, Ontario - A powerful act of generosity has given 10-year-old Melanie Bourdon the ability to reach new heights.                             The Cornwall girl was diagnosed with Morquio A Syndrome (MPS IVA) at the tender [...]